GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oragenics Inc (AMEX:OGEN) » Definitions » Forward PE Ratio

OGEN (Oragenics) Forward PE Ratio : 0.00 (As of Apr. 26, 2025)


View and export this data going back to 2003. Start your Free Trial

What is Oragenics Forward PE Ratio?

Oragenics's Forward PE Ratio for today is 0.00.

Oragenics's PE Ratio without NRI for today is 0.00.

Oragenics's PE Ratio (TTM) for today is 0.00.


Oragenics Forward PE Ratio Historical Data

The historical data trend for Oragenics's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oragenics Forward PE Ratio Chart

Oragenics Annual Data
Trend
Forward PE Ratio

Oragenics Quarterly Data
Forward PE Ratio

Competitive Comparison of Oragenics's Forward PE Ratio

For the Biotechnology subindustry, Oragenics's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oragenics's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oragenics's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Oragenics's Forward PE Ratio falls into.


;
;

Oragenics Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Oragenics  (AMEX:OGEN) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Oragenics Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Oragenics's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Oragenics Business Description

Traded in Other Exchanges
Address
1990 Main Street, Suite 750, Sarasota, FL, USA, 34236
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The Company operates in one reportable segment, which includes activities related to advancing the development of its concussion drug, ONP-002.
Executives
Alan W Dunton director VICURON PHARMACEUTICALS INC, 455 S GULPH ROAD SUITE 305, KING OF PRUSSIA PA 19406
Fred Telling director 501 ELLIOTT AVE. W., SUITE 400, SEATTLE WA 98119
John P Gandolfo director 62 TERRACE ROAD, WAYNE NJ 07470
Cassidy Bruce A. Sr. director C/O LOOP MEDIA, 700 N CENTRAL AVENUE, SUITE 430, GLENDALE CA 91203
Janet Huffman officer: CFO, Secretary and Treasurer 5317 FRUITVILLE RD SUITE 6, SARASOTA FL 34232
Robert C Koski director, 10 percent owner 1500 W UNIVERSITY PARKWAY, SARASOTA FL 34243
Michael O'keefe Sullivan officer: CFO, Secretary and Treasurer 3000 BAYPORT DRIVE, SUITE 685, TAMPA FL 33607
Joseph Hernandez 10 percent owner C/O MICROLIN BIO, INC., NEW YORK NY 10022
Kimberly M Murphy director 101 EAST KENNEDY BLVD., SUITE 2800, TAMPA FL 33602
Koski Family Lp 10 percent owner 1500 W UNIVERSITY PARKWAY, SARASOTA FL 34243
Randal J Kirk 10 percent owner 1881 GROVE AVENUE, RADFORD VA 24141
Alan Joslyn director, officer: CEO and President 39 OLD RIDGEBURY ROAD, DANBURY CT 06810
Charles L Pope director 4902 EISENHOWER BOULEVARD, TAMPA FL 33634
Christine L Koski director, 10 percent owner 1500 WEST UNIVERSITY PARKWAY, SARASOTA FL 34243
Thomas L Koski 10 percent owner

Oragenics Headlines

From GuruFocus